First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA SEE THE DATA
3 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. Read more
*Estimates of patients treated reflect global data since launch (Apr 2014-Aug 2022; US=approximately 60% of data). Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
FDA, U.S. Food and Drug Administration; PsA, psoriatic arthritis; TB, tuberculosis.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Otezla® (apremilast) FDA approval letter. March 21, 2014.
While pursuing coverage, commercially insured patients can enroll in the combined Otezla Co-Pay Card * and Bridge Program † to start and stay on Otezla as prescribed for as little as $0.
*The Otezla Co-Pay Card is for eligible commercially insured patients. Terms, conditions, and program maximums apply. Other restrictions may apply. Click here for full Terms and Conditions. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law. Patients who are not eligible can call 1-844-4OTEZLA (1-844-468-3952) to discuss further financial support opportunities. †If the patient’s health plan requires a prior authorization, or if patient experiences a delay in obtaining approval for Otezla, patients can qualify for the Bridge to Commercial Coverage Offer and receive Otezla free for up to 12 months while pursuing approval from their health plans. No purchase necessary. Click here for full Terms and Conditions.
‡Support provided through independent nonprofit foundations and not through Otezla SupportPlus. Otezla SupportPlus has no control over independent, third-party programs and provides referrals as a courtesy only.
The Otezla Nurse Partner § program works closely with your new Otezla patients to provide tailored support, including how to get started on Otezla, maintaining a treatment routine, and guiding them to resources based on their individual goals.
Enrollment is simple for your Otezla patients. Encourage them to sign up for Otezla SupportPlus to access the Otezla Nurse Partner program today!
§Otezla Nurse Partners are nurses by training, but they are not part of a patient’s treatment team or an extension of their doctor’s office. Patients will be referred to their doctor’s office for clinical advice.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for the full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for
phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.